WuXi Biologics investing $60 million to set up first US biologics production facility

Date Published06/11/2018
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name WuXi Biologics
Parent companyWuXi Pharma Tech
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):150
Capital investment ($):60
Country(ies) from which reshored:Hong Kong
City reshored to:Worchester
State(s) reshored to:MA
If relevant, work nearshored to:-
Product(s) reshoredbiopharmaceuticals
What domestic positive factors made reshoring more attractive?Customer responsiveness improvement, Eco-system synergies, Government Incentives, Higher productivity, Infrastructure, Lead time/Time to market, Proximity to customers/market, Skilled workforce availability/training
Find Reshoring Articles